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Abstract 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by the 
expansion of a CAG trinucleotide repeat in the IT-15 gene. This disorder is characterized by 
progressive neuronal death in the basal ganglia and cortex. Although many years have passed 
since the discovery of the HD mutation, no therapy has shown a neuroprotective effect or has been 
shown to slow down the disease progression to date. Growing evidence supports a pivotal role for 
mitochondrial dysfunction in the death of patients’ neurons but the molecular bases for 
mitochondrial impairment have not yet been elucidated. We provide the first evidence of an 
abnormal activation of Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (BNip3) in cells 
expressing mutant huntingtin. In the present study we show abnormal accumulation and 
dimerization of BNip3 in mitochondria from human HD muscle cells and brain tissues from HD 
model mice. Recent results have suggested that cytotoxicity induced by mutant huntingtin is likely 
mediated by an alteration in normal mitochondrial dynamics, resulting in increased mitochondrial 
fragmentation. According to the literature, when BNip3 is overexpressed or induced, it localizes to 
the mitochondria and causes loss of mitochondrial potential, mitochondrial fragmentation and 
mitophagy. In this context, BNip3 could have a key role in mediating the impairment of 
mitochondrial dynamics in HD cells, and BNip3 blocking could improve mitochondrial function, 
representing a new therapeutic strategy for HD. We have characterized the effects of BNip3 
blockade in cell culture model of HD by expression of the dominant negative protein BNip3∆TM. 
BNip3∆TM is a mutant protein deleted of the C-terminal domain that is necessary for BNip3 
insertion into the outer mitochondrial membrane. 
Importantly, we have demonstrated that blocking BNip3 expression and dimerization was able to 
restore normal mitochondrial phenotype in human HD muscle cells. Our data shed light on the 
molecular mechanisms underlying mitochondrial dysfunction in HD and point to BNip3 as a new 
potential target for neuroprotective therapy in HD.  
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State of the Art 
 
Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor 
disturbances, cognitive decline and behavioral changes. The disease has an autosomal dominant 
pattern of inheritance and an age-dependent penetrance. HD has a prevalence of 3-10 affected 
subjects per 100000 individuals in Western Europe and North America (Ho et al., 2001). Onset is 
most commonly in adulthood at about 40 years, with a typical duration of 15-20 years before 
premature death. The disorder was first described in the 19th century by George Huntington, but it 
was only the 1993 that the causative gene was finally isolated (The Huntington’s Disease 
Collaborative Research Group, 1993). The disorder is caused by an expanded trinucleotide (CAG) 
repeat in the first exon of the IT-15 gene, which is located on the short arm of chromosome 4 
(4p16.3). The IT-15  gene encodes a protein named huntingtin (htt) and the CAG  expansion 
encodes an expanded polyQ stretch in the htt protein. Normal alleles contain 35 or less CAG 
repeats while mutant alleles are associated with 36 or more CAG repeats, although alleles with 36 
to 39 repeats are considered to have reduced-penetrance.  
The neurons of HD patients progressively die as the disease progresses, leading to widespread 
atrophy of the striatum and cortex, which account for the clinical symptoms of the disease. In the 
postmortem brains of patients with HD, extensive medium spiny neuronal loss was observed in the 
striatum and loss of pyramidal neurons was observed also in the cerebral cortex and hippocampus 
(Vonsattel and DiFiglia, 1998). The causes of selective and premature death of medium spiny 
projection neurons are not completely understood. Furthermore, HD is a multisystem disorder, 
wild-type (wt) and mutant htt (mhtt) proteins are expressed ubiquitously in the central and 
peripheral nervous systems of patients with HD. Htt is a large protein of unknown function without 
structural homology with any other known protein; however, deletion of the HD gene results in an 
early embryonic lethality (Duyao et al., 1995), revealing a role for the protein during the 
development. Within the cell wt htt is mainly localized in the cytoplasm associated with organelles 
(mitochondria, the Golgi apparatus, the endoplasmic reticulum, synaptic vesicles and several 
components of the cytoskeleton), but it is also present inside the nucleus, although to a lesser 
extent. Htt plays a role in protein trafficking, vesicle transport, postsynaptic signaling, 
transcriptional regulation, and apoptosis. The mutant protein has been shown to disrupt several of 
these intracellular pathways by abnormally interacting and/or sequestering key components of 
these multiple pathways, therefore the expanded polyglutamine is believed to confer a new 
function to htt that is toxic to the cell (toxic gain of function). On the other hand, several lines of 
evidence also suggest that a loss of function of wt htt also contributes to the disruption of 
intracellular homeostasis, culminating in neuronal dysfunction and death. Thus, a loss of function 
of the wt protein and a toxic gain of function of the mhtt contribute to the disruption of multiple 
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intracellular pathways. Various mechanisms of neurodegeneration such as mitochondrial 
dysfunction, oxidative stress, excitotoxicity, dopamine toxicity, metabolic impairment, apoptosis 
and autophagy have been implicated in HD. All these mechanisms are likely to occur in parallel 
and promote each other, ultimately culminating in neuronal loss. 
Current therapies for HD provide control of some of the major troublesome signs and symptoms 
(chorea, psychosis, depression). However, these treatments are only “symptomatic”, meaning that 
they ameliorate the clinical features of the illness, but the benefits are only temporary and 
disappear when the treatment is stopped. To date there are no drugs or agents available to treat or 
delay or prevent HD progression. Research’s ultimate goal is to facilitate the development of 
therapeutic strategies for curing the disease or, as an alternative, for slowing or stopping its 
progression.  
 
Mitochondrial defects in HD 
Growing evidence suggests that mitochondrial dysfunction has a key role in HD pathogenesis 
(Browne, 2008). In particular, observations that mitochondrial changes detected in HD genetic 
models are very early events that precede disease onset support the hypothesis that mitochondrial 
impairment may occur early enough to contribute to the underlying pathogenetic mechanisms.  
Several studies suggest that abnormal mitochondrial bioenergetics is involved in HD pathogenesis. 
Studies in HD patients have shown a significant decrease in glucose uptake in the cortex and 
striatum ( Kuhl et al., 1982). Magnetic resonance imaging spectroscopy (MRI) showed increased 
production of lactate in cerebral cortex and basal ganglia from HD patients (Jenkins et al., 1993; 
Koroshetz et al., 1997). Studies using MRI of postmortem brains from HD patients revealed a 
progressive atrophy of the striatum, compared to brain images of age-matched control subjects 
(Bamford et al., 1989).  Biochemical studies of brain tissue from HD patients have demonstrated 
multiple defects in the caudate, as a reduced activity of several components of oxidative 
phosphorylation (Stahl and Swanson, 1974; Butterworth et al., 1985). Striatal cells derived from a 
knock-in mouse model of HD show significantly diminished oxidative phosphorylation indicated by 
lower respiration and mitochondrial ATP production rates compared to wild-type cells (Milakovic  
and Johnson, 2005). Also ultrastructural abnormalities in mitochondria have been described in HD 
cortical tissue (Gardian and Vecsei, 2004). Studies on peripheral tissues and peripheral cells 
(fibroblasts, lymphoblasts and myoblasts) from HD patients have identified several mitochondrial 
abnormalities, including a decreased activity of respiratory chain enzymatic complexes, a 
decreased ATP/ADP ratio and an altered morphology of these organelles (Squitieri et al., 2010; 
Costa et al., 2010). Overall, findings from these studies suggest that defective mitochondrial 
bioenergetics plays a large role in the progression and pathogenesis of HD. 
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Mitochondria have an essential role in the physiology of eukaryotic cells; not only do they produce 
most of the cell’s ATP but they also participate in ion homeostasis, regulation of the cell’s redox 
state, lipid and amino-acid metabolism, as well as in regulation of programmed cell death. All these 
functions are highly dependent on the mitochondrial electrochemical transmembrane potential 
(∆ψm), a physicochemical parameter consisting of two components, namely the total 
transmembrane electrical potential (voltage gradient) and the proton gradient that is physiologically 
generated across the inner mitochondrial membrane by the activity of the respiratory chain. 
Growing evidence indicates that the many mitochondrial abnormalities observed in HD tissues may 
stem from an abnormal ∆ψm, as the mitochondria extracted from HD patients had ∆ψm values lower 
than the mitochondria from normal patients (Sawa et al., 1999; Panov et al., 2002; Ciammola et al., 
2006; Almeida et al., 2008). ∆ψm loss seems to be a direct effect of mhtt, given that it occurs in 
normal cells transfected with mhtt (Bae et al., 2005; Benchoua et al., 2006), and when mhtt is 
added to mitochondria isolated from normal brains (Panov et al., 2003). The results from these 
studies notwithstanding, the molecular bases for the ∆ψm decrease observed in HD cells still 
remain elusive. Depolarization of mitochondria is known to induce their fragmentation into multiple 
smaller organelles (Legros et al., 2002) by inhibiting organelle fusion. Furthermore recent studies 
uncovered an interplay between HD and mitochondrial dynamics. Once thought to be static in their 
organization, mitochondria are now considered to constitute a population of organelles that migrate 
throughout the cell, fuse and divide (fusion and fission mechanisms), and undergo regulated 
turnover. Studies performed over the past decade, revealed that mitochondria form a wide network 
of long tubules called mitochondrial network and that mitochondrial energy production is controlled 
by elongation or fragmentation of the tubular network organization. They also revealed that 
disruption of mitochondrial dynamics and bioenergetic defects are closely linked showing that the 
pathological contexts determine modifications of the mitochondrial−network that in turn controls 
bioenergetics (Benard and Rossignol, 2008). In particular, several observations indicate that 
mitochondria undergo rapid, extensive fragmentation early in several cell death pathway thus 
suggesting a relationship between mitochondrial dynamics and apoptotic conditions (Knott et al., 
2008). In healthy neurons, fission and fusion mechanisms balance equally to maintain tubular 
mitochondrial shape. But there is important evidence to suggest that in HD the balance between 
mitochondrial fission and fusion is abnormal and that HD cells are characterized by mitochondrial 
fragmentation. HeLa cells overexpressing a mhtt with a 74 glutamine repeats show fragmentation 
of mitochondria, reduced mitochondrial fusion, reduced ATP and increased cell death (Wang et al., 
2009). Remarkably, expression of either dominant−negative Drp1 (a protein that induce 
mitochondrial fission) or Mfn2 (protein that induce mitochondrial fusion) not only prevents this 
change in mitochondrial morphology, but also restores ATP levels and attenuates cell death. 
Moreover, according to a recent report, various cellular models of HD (including immortalized 
striatal cell lines isolated from knock−in HdhQ111 mouse, primary striatal neurons from YAC128 
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mice and lymphoblasts from HD patients) are characterized by mitochondrial fragmentation and 
cristae alterations (Costa et al., 2010). Overall these data suggest that mhtt causes an impairment 
of mitochondrial dynamics. 
 
BNip3 
Bcl-2/adenovirus E1B 19-kDa interacting protein 3 (BNip3) is a member of the so-called BH3-only 
subfamily of Bcl-2 family proteins that regulate the permeability state of the outer mitochondrial 
membrane (OMM). This regulation is accompanied by the formation of homo- and hetero-
oligomers inside the membrane, which influences ∆ψm and controls cell death mechanisms (Harris 
et al., 2000; Frazier et al., 2006). The BNip3 protein is normally present in the brain tissue and 
skeletal muscle (Lee et al., 2006) and is mainly localized in the cytoplasm and nucleus or is found 
loosely associated with the mitochondrial membrane in an inactive conformation (Burton et al., 
2006; Webster et al., 2005). The molecular mechanism underlying BNip3 activation is not 
completely understood, but it probably involves a multi- step process. A few intracellular toxic 
stimuli, such as decreased intracellular pH and increased cytosolic calcium concentration (Webster 
et al., 2005; Graham et al., 2007), can induce BNip3 integration into the OMM with the protein’s N 
terminus in the cytoplasm and C terminus inside the mitochondria (Vande Velde et al., 2000). The 
BNip3 C-terminal hydrophobic domain is required for integration in the OMM, as its deletion 
prevents the mutant protein (BNip3∆TM) from integrating into the OMM and inducing cell death 
(Ray et al., 2000; Kim et al., 2002). Once integrated into the OMM, BNip3 can self-associate and 
form stable homodimers on the basis of intermonomeric helix–helix polar interactions of various 
side chains (Bocharov et al., 2007). The unique structure of the transmembrane domain suggests 
that BNip3 dimers could function as proton channels in the OMM, thereby increasing ion 
conductance (Bocharov et al., 2007).  BNip3 integrates into the OMM through its C terminal 
transmembrane domain (TM) leaving the last 10 residues into the intermembrane space (Vande 
Velde et al., 2000), where it can interacts with the pro-fusion protein OPA1 altering the 
mitochondrial dynamics (Landes et al., 2010). Several studies have previously reported that BNip3 
can cause changes in mitochondrial morphology in cell lines. A lot of evidence shows that 
activated BNip3 induces mitochondrial fragmentation and mitophagy. In fact the examination of 
mitochondria in BNip3-overexpressing cardiac myocytes reveals extensive fragmentation of the 
mitochondrial network (Hamacher Brady et al., 2007). Moreover, overexpression of HA-BNip3 in 
HeLa cells results in fragmentation of mitochondria and this fragmentation depends on Drp1 
activity (Landes et al., 2010). The dominant-negative mutant BNip3∆TM is able to interact with 
wild-type BNip3 and block its integration into the OMM (Hamacher-Brady et al., 2007; Kubasiak et 
al., 2002; Regula et al., 2002). The overexpression of BNip3∆TM results in normal filamentous 
mitochondrial network (Hamacher-Brady et al., 2007).
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Aim of the Project 
 
The importance of mitochondria in HD pathogenesis has long been investigated, but research on 
how mhtt affects the mitochondrial functions and dynamics (fission and fusion, fragmentation and 
mitophagy) is still lacking. To date there are no reported studies about the role of BNip3 protein as 
mediator of mitochondrial functions and dynamics in HD. Considering the crucial role of BNip3 in 
regulating OMM permeability and of mitochondrial dynamics, we have undertaken a study to 
investigate the potential role of BNip3 in the mitochondrial dysfunction induced by mhtt. 
 
The first aim of the current study was to investigate the role of BNip3 in mhtt expressing cells and 
mouse model of HD. To address the role of BNip3 in HD we examined its activation and 
mitochondrial localization. This study was carried out using cell and mouse models of HD. Data 
regarding BNip3 activation and localization were investigated in brain tissues from R6/2 and YAC 
mice (mouse models of HD) and in primary cells obtained from muscular biopsies from HD 
patients. 
 
The second aim of the current study was to characterize the downstream effects of BNip3 
activation on mitochondria in HD.  We performed these analyses in HD neuronal cell models 
(mouse striatal cell line) and in primary cells obtained from muscular biopsies from HD patients. In 
vitro HD cell cultures were analyzed for mitochondrial morphology and parameters (including 
mitochondrial potential, mitochondrial mass, ATP synthesis and oxygen consumption). 
 
The third aim of the current study was to investigate therapeutic strategies connected to BNip3 
inactivation in cell models. We analyzed whether BNip3 can be considered a therapeutic target to 
improve mitochondrial function in HD. Therefore we addressed what would happen in mhtt 
expressing cells when transfected with BNip3∆TM. We transiently expressed BNip3∆TM in HD 
neuronal cell models and HD myoblast cells in order to verify if the expression of the dominant 
negative form of BNip3 was able to restore the normal mitochondrial phenotype. 
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Main Results 
 
Increased BNip3 levels and mitochondrial localization in muscle cells from HD patients. 
  
To investigate the potential role of BNip3, we analyzed its expression levels in muscle cell lysates 
from four HD and four control subjects by SDS-PAGE. According to the literature peripheral cells of 
HD patients display mitochondrial abnormalities related to mhtt expression (Sassone et al., 2009). 
In particular, HD muscular cells are a useful cell culture model that mirrors many mhtt related 
dysfunctions that have been shown in neuronal cells (Ciammola et al., 2006; Ciammola et al., 
2010).  
The molecular weight of BNip3, as predicted from its amino-acid sequence, is 21.5 kDa; however, 
the protein has been described to migrate as two major molecular species, with apparent 
molecular weights of ~30 and ~60 kDa in SDS-PAGE gels, representing monomeric and dimeric 
forms, respectively (Chen et al., 1997; Mellor and Harris, 2007). The apparent molecular weight of 
monomeric BNip3 in SDS-PAGE and the presence of multiple protein bands at ~30 kDa are likely 
due to protein phosphorylation, as BNip3, similar to many proteins of the Bcl-2 family, bears 
consensus sites for phosphorylation by protein kinases (Graham et al., 2007).The biological role of 
these possible posttranslational modifications still remains unknown. The BNip3 signal at ~60 kDa, 
corresponding to BNip3 dimers, can be detected by SDS-PAGE, as BNip3 dimers are highly stable 
and resistant to detergents (Chen et al., 1997; Tracy and Macleod, 2007). In cell lysates from 
human HD myoblasts, we detected monomeric BNip3. Densitometric analysis showed higher 
levels of monomeric BNip3 in HD myoblasts than in myoblasts extracted from control subjects. 
Dimeric BNip3 was barely detectable in total lysates of human myoblasts (Fig. 1a ). As the pivotal 
step in BNip3-mediated cell death involves its integration into the OMM (Vande Velde et al., 2000), 
we tested whether the increased expression of BNip3 resulted in increased mitochondrial 
localization. Mitochondria-enriched fractions were prepared from normal and HD human muscle 
cells and then treated by alkaline pH. This treatment detaches loosely associated peripheral 
membrane proteins (Goping et al., 1998), thus enriching the samples for mitochondrial 
transmembrane proteins. Immunoblot analysis of alkali-treated mitochondrial fractions showed 
strong monomeric BNip3 signals in both HD and control myoblasts. However, there was a trend of 
increased monomeric BNip3 in HD samples. The dimeric form of BNip3 was visible only in the HD 
mitochondria and was not detectable in control myoblasts (Fig. 1b). HD myoblasts derived from 
patients carrying 60 CAG repeats (lane 6) had the highest dimeric BNip3 signal. To confirm the 
increased association of BNip3 with the HD mitochondria, we performed confocal microscopy on 
myoblasts obtained from control and HD patients. Notably, BNip3 colocalized with the mitochondria 
in ~40% of HD cells, while the protein was mainly localized in the cytoplasm and in the nucleus in 
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control cells (Fig. 1c). Overall, our data suggest the accumulation and dimerization of BNip3 
protein in the mitochondria of human HD muscle cells.  
 
 
BNip3 levels in the brain tissue from R6/2 and YAC128 mouse models.  
 
To investigate whether the changes observed in BNip3 expression and localization in muscle cells 
obtained from HD patients mirrored events occurring in the CNS, we analyzed BNip3 levels and 
localization patterns in the brain tissues of two different HD model mice, namely R6/2 and yeast 
artificial chromosome (YAC)128. R6/2 mice are transgenic for exon-1 of the human IT-15 gene, 
containing highly expanded CAG repeats (Mangiarini et al., 1996), whereas YAC128 mice express 
a full-length IT15 gene with 128 CAG repeats (Hodgson et al., 1999). There was a trend of 
decreased monomeric BNip3 in HD striatum samples (Fig. 2a); no significant difference in BNip3 
expression was observed in the cortex from R6/2 and littermate control mice at 10 weeks of age 
(Figure 2b). It is noteworthy that immunoblotting analysis of alkali-treated mitochondrial fractions 
showed a stronger dimeric BNip3 signal in the R6/2 striatum than in the wild-type striatum (Fig. 2c). 
In R6/2 mitochondrial fractions, we also observed an anti-BNip3-immunoreactive band with an 
apparent molecular weight >60 kDa, which is consistent with previously described higher-order 
oligomeric forms of BNip3 (Frazier et al., 2006; Gao et al., 2005). Immunoblotting analysis of 
cortical mitochondrial fractions showed a slight increase in the dimeric BNip3 signal in the R6/2 
striatum than in the wild-type striatum, but the difference did not reach statistical significance (Fig. 
2d). In the striatum of 6-month-old YAC128 mice, levels of monomeric and dimeric BNip3 were 
significantly increased with respect to control littermates (Fig. 2e). Expression levels in the cortex 
showed a high degree of variability among the animals analyzed, and mean differences between 
control and HD mice did not reach statistical significance (Fig. 2f). However, the variance in the 
distribution of BNip3 levels in the HD group was significantly different from the variance in the 
control group of animals, suggesting a trend toward increased BNip3 levels in HD cortexes. Similar 
to R6/2 animals, the mitochondria from the YAC128 striatum contained more BNip3 than those 
from the control striatum (Fig. 2g). No difference in BNip3 level was detected between the YAC128 
cortical mitochondria and the mitochondria from control cortexes (Fig. 2h). 
 
 
Increased resistance of monomeric BNip3 in HD samples to proteinase-K digestion.  
 
One proposed model to explain BNip3 function posits that BNip3 can exist as an inactive, latent 
monomer, which requires a death activation signal to become active (Tracy and Macleod, 2007). 
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The death signal elicits a conformational change in monomeric BNip3 that promotes protein 
dimerization or oligomerization in the lipid environment of the mitochondrial membrane and the 
formation of an ion-permeable channel through the OMM. Thus, a conformational change in the 
monomeric form is believed to be the triggering event in BNip3 activation and mitochondrial 
membrane permeabilization. To assess potential differences in the conformational state of 
monomeric BNip3 induced by mutant htt, we tested BNip3 resistance to in vitro digestion with 
proteinase-K (PK) in whole extracts of HD samples. This approach has been successfully used to 
discriminate between inactive (more prone to digestion) and active (more resistant) forms of 
monomeric BNip3 in a previous study (Frazier et al., 2006). The increased resistance of the active 
monomeric form to PK digestion is presumably due to the acquisition of a proteolysis-resistant 
conformation (Frazier et al., 2006). Total lysates prepared from control and HD myoblasts were 
digested with increasing concentrations of PK, and the products were analyzed by immunoblotting. 
As shown in Fig. 3a, BNip3 monomers in cell lysates from HD myoblasts were significantly more 
resistant to PK digestion than those from control samples. Actin digestion was not different 
between HD and control samples (Fig. 3a), demonstrating that the increased resistance to 
proteolysis in HD samples was specific for the BNip3 protein. Similar results were obtained using 
total protein extracts from R6/2 and control mouse brains (Fig. 3b). Overall, our data support the 
hypothesis that mutant htt promotes a conformational change in the BNip3 protein that may trigger 
its activation.   
To further confirm that BNip3 activation in HD sample involve a post-trascriptional mechanism, we 
evaluated BNip3 mRNA expression by real-time PCR experiments. We firstly examined the 
expression pattern of BNip3 in HD and control myoblasts. Results showed a slight increase in 
BNip3 mRNA in HD myoblasts compared with control myoblasts (Fig.4a). No difference in BNip3 
mRNA was detected in R6/2 brains compared with brains of littermate controls, and in YAC128 
brains compared with wild-type brains (Fig. 4b-c). 
 
 
Decreased JC−1 ratio in HD cells. 
 
JC−1 is a mitochondrial dye that stains mitochondria in living cells in a membrane 
potential−dependent fashion, but JC−1 fluorescence is dependent also on the mitochondrial mass 
content.  JC−1 ratio is widely used to measure the ∆ψm. Ciammola et al. previously reported that 
HD myoblasts have ∆ψm value that is decreased by ~30% compared with control myoblasts 
(Ciammola et al., 2006). We have analyzed mitochondrial ∆ψm in a mouse cell model of HD. 
Striatal cell lines have been established by Trettel and colleagues from HD knock in 
(HdhQ111/Q111) and wild−type (HdhQ7/Q7) mice (Trettel et al., 2000). The STHdhQ111/Q111 
cell line expresses mhtt at endogenous levels, and therefore it is a genetically accurate cell model 
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of HD. As the striatum is the most affected region in HD, the striatal origin of this cell model makes 
it optimal for HD studies. 
We measured JC−1 ratio in STHdh cells maintained in mild metabolic stress condition for three 
days, by using a medium that forces cells to depend on mitochondrial respiration for energy 
production (DMEM without D−glucose supplemented with 10% fetal bovine serum, 5mM galactose, 
5 mM sodium pyruvate; see references Robinson et al., 1992, Palmfeldt et al., 2009). We observed 
that ∆ψm was decreased by ~ 70% in STHdhQ111/Q111 cells compared to STHdhQ7/Q7 (Fig. 5; 
**p< 0.01). 
 
 
Decreased mitochondrial mass content in HD cells. 
 
We further examined mitochondrial mass in STHdhQ7/Q7 and STHdhQ111/Q111 cells 
(maintained in mild metabolic stress condition for three days as described in the previous 
paragraph) loading the cells with the mitochondria specific dye MitoTracker Green FM (Agnello et 
al., 2008). MitoTracker is a fluorescent dye that localizes to the mitochondrial matrix regardless of 
the mitochondrial membrane potential and covalently binds to mitochondrial proteins by reacting 
with free thiol groups of cysteine residues.  
Fluorescent cells were then analyzed with a FACScan flow cytometer. The data confirmed that 
STHdhQ111/Q111 cells had a reduced mitochondrial mass compared to control cells (Fig. 6a).  
To test whether lower mitochondrial content is associated with the expression of mhtt in human 
myoblasts we measured mitochondrial DNA copy number by real time PCR in 8 control myoblasts 
and 6 HD myoblasts. Relative mitochondrial DNA copy number was quantified by the ratio of 
mitochondrial gene (mitochondrial D-loop) to a nuclear gene (RNaseP) and  the mean mtDNA 
content (expressed as the relative number of mtDNA copies per nuclear genome) was 4646 in the 
control myoblasts and 4107 in HD myoblasts (Fig.6b). Results indicate that HD muscle cell cultures 
display a trend in reduction of mitochondrial DNA copy number as compared to control myoblasts, 
which is consistent with results obtained in STHdh cells and with literature. We need to replicate 
this experiment in a larger cohort of muscle cells. 
 
 
Increased mitochondrial fragmentation in cells expressing mhtt 
 
To better understand the possible involvement of BNip3 activation in the mitochondrial alteration 
induced by mhtt, we examined mitochondrial morphology in STHdh cells. STHdhQ7/Q7 and 
STHdhQ111/Q111 cells were transiently transfected with plasmid encoding mitochondrially 
targeted fluorescent protein (pDsRed2−Mito) and 400 randomly chosen cells per group were 
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analyzed by fluorescence microscopy. Cells were analyzed by two different blinded observers and 
scored as containing predominantly fragmented or predominantly elongated mitochondria 
according to a described protocol (Chen et al., 2005). No differences were observed between 
STHdhQ7/Q7 and STHdhQ111/Q111 cells maintained in normal growth conditions (DMEM 
supplemented with 10% fetal bovine serum) but when cell cultures were exposed to mild metabolic 
stress for three days, STHdhQ111/Q111 cells exhibited an increased mitochondrial fragmentation 
as compared to STHdhQ7/Q7. Figure 7a is representative of the analyzed images. As shown in 
figure 7b, about 81% of STHdhQ111/Q111 cells after three days in galactose medium  displayed 
fragmented mitochondria and only 19% contained elongated mitochondria, whereas 40% of 
STHdhQ7/Q7 had elongated mitochondria (Fig. 7b; chi−square test, p<0.01). When cell cultures 
were exposed to mild metabolic stress for six days we have obtained similar results (Fig. 7c; chi-
square test, p<0.05). To better describe the morphometry of the mitochondrial network, we 
analyzed the confocal fluorescence images for an automated shape−analysis of the mitochondrial 
structures. By means of ImageJ 1.42, raw images were binarized, mitochondrion number (nc), area 
and outline were measured and the form factor was calculated (defined as [Pm2]/[4πAm]), where Pm 
is the length of the mitochondrial outline and Am is the area of the mitochondrion. The form factor 
allows quantifying the degree of branching of the mitochondrial network. Images of twelve 
randomly selected cells per genotype were analyzed (Koopman WJ et al., 2006). FF was lower in 
STHdhQ111/Q111 compared to STHdhQ7/Q7, this data confirms a decrease of mitochondrial 
length and branching in HD cells (Fig. 7d represents mean ± SEM; *p<0.05 vs STHdhQ7/7). The 
analysis also revealed that STHdhQ111/Q111 cells had a lower number of mitochondria per cell 
(Fig. 7e represents mean ± SEM; *p<0.05 vs STHdhQ7/7).  
We next analyzed mitochondrial morphology in in vitro muscular cells obtained from muscular 
biopsy of HD patients. Myoblasts from 3 HD patients (CAG repeat on the upper allele were 59, 50 
and 50) and 3 healthy controls were transfected with pDsRed2−Mito and a comparative analysis of 
mitochondrial morphology was performed. Figure 8a is representative of the analyzed images. For 
each subject 300 cells were randomly chosen and scored into three categories. Class I cells: 
complete fragmentation resulting in only mitochondrial spheres; Class II cells: extensive 
fragmentation but contained some very short mitochondrial rods (<5 µm in length); Class III cells: 
cells with medium−length mitochondrial tubules (>8 µm in length). The analysis in three categories 
was possible as myoblasts are bigger compared to STHdh cells (nuclei of myoblasts measure ~ 
15−20 µm whereas nuclei of STHdh cells measure <10 µm). This allows us to better evaluate the 
skeleton of the mitochondrial network. Our data showed that HD myoblasts displayed an increased 
percentage of class I and decreased percentage of class III as compared to control myoblasts. An 
extensive fragmentation (Class I) was observed in 37.5% of HD cells, 50% of cells contained short 
rods in addition to mitochondrial spheres (Class II) and only 12.5% of cells contained 
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medium−length tubules (Class III), whereas only 12.5% of control myoblasts contained completely 
fragmented mitochondria (Class I) (Fig. 8b shows mean±SEM; chi−square test, p<0.01). 
 
 
Reduced ATP synthesis and oxygen consumption in STHdh cells.  
 
STHdh cells were exposed to mild metabolic stress and nucleotides in cellular extracts were 
measured by HPLC analysis in order to quantify mitochondrial ATP production. Data were 
normalized on cell number assessed by Coulter Counter assay. ATP concentration  in 
STHdhQ111/Q111 was decreased by 62% compared to STHdhQ7/Q7 cells (Fig. 9a-b. Fig. 9b 
represents mean±SEM deriving from four independent experiments; *p< 0.05 ).   
We measured oxygen consumption in STHdh cells using a Clark−type polarographic oxygen 
electrode. A total of 106 cells were maintained in suspension in oxygen electrode buffer at 33° C 
throughout each experiment. We observed that STHdhQ111/Q111 cells have significantly reduced 
oxygen consumption rate (OCR) (6.125±0.79 nmol O2/min/106 cells) compared with wild−type 
cells. (8.996±0.93 nmol O2/min/106 cells) (Fig. 10 represents mean±SEM deriving from six 
independent experiments; *p< 0.05). 
 
 
BNip3∆TM expression improves mitochondrial membrane potential and restores normal 
mitochondrial morphology in human HD myoblasts. 
 
As BNip3 integration into the OMM can elicit the reduction of ∆ψm on various toxic stimuli (Lee and 
Paik, 2006), we hypothesized that the high BNip3 levels we found associated with mitochondrial 
membrane fractions in HD cells could cause a decrease in ∆ψm, previously observed in HD 
myoblasts and other HD models (Sawa et al., 1999; Ciammola et al., 2006; Benchoua et al., 2006; 
Bae et al., 2005). In this context, we reasoned that blocking both BNip3 integration in the OMM and 
BNip3 dimerization by overexpression of the dominant-negative protein BNip3∆TM would protect 
cells from the mitochondrial depolarization induced by mhtt. The mutant BNip3∆TM lacks the C-
terminal domain essential for integration into the OMM and has been shown to function as a 
dominant-negative mutant that blocks BNip3 translocation and integration into the OMM 
(Hamacher-Brady et al., 2007; Kubasiak et al., 2002). In human HD myoblasts, transient 
transfection with BNip3∆TM did not modify mitochondrial ∆ψm both in control and HD myoblasts 
(data not shown), probably because of high endogenous levels of BNip3 and the low transfection 
efficiency of plasmid DNA in primary myoblasts (~60% of cells displayed green fluorescence 24 
hours after trasfection with the pEGFP vector). However, co-transfection of cells with BNip3∆TM 
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and with short interfering RNA (siRNA) to knock down endogenous BNip3 resulted in an efficient 
silencing of the endogenous protein (by ~70%, Fig. 11a), in a detectable expression of BNIP3∆TM, 
as well as in a significant increase in ∆ψm in all four HD lines transfected (mean value 124%, 
**p<0.01; Fig. 11b). Overall, these results suggest that the ∆ψm loss in HD myoblasts may stem 
from BNip3 activation and that BNip3∆TM expression resulted after 24 hours in a significant 
increase in ∆ψm. Overexpression of the mutant protein BNip3∆TM and silencing of endogenous 
BNip3 protect HD myoblasts from the mitochondrial depolarization induced by mutant htt. 
We next verified whether the overexpression of BNip3∆TM protein could normalize mitochondrial 
morphology in HD human myoblasts. We co-transfected myoblasts from 3 HD patients (CAG 
repeat on the upper allele were 59, 50 and 50) and 3 healthy controls with pDsRed2−Mito and with 
pBNip3∆TM and 24 hours after transfection we analyzed mitochondrial morphology according to 
the above described criteria. For each subject 300 cells were randomly chosen and scored into the 
three categories. HD cells designated as class I lowered from 37.5% to 10%, whereas class II and 
class III percentage respectively increased from 50% to 66.7% and from 12.5% to 23.3% (Fig. 11c; 
chi−square test, p<0.01).Therefore the expression of BNip3∆TM was able to restore mitochondrial 
elongation in HD myoblasts without causing any changes in mitochondrial morphology in control 
myoblasts. 
 
 
BNip3∆M expression restores normal mitochondrial morphology and improves 
mitochondrial function in STHdhQ111/111 cells. 
 
We cotransfected STHdh cells with pDsRed2−Mito and pBNip3∆TM and 3 days after transfection 
we analyzed mitochondrial morphology according to the above described criteria. BNip3∆TM 
overexpression striking decreased the mitochondrial fragmentation observed in mutant cells, 
leading to an increase of mitochondrial medium−length tubules in STHdhQ111/Q111 cells from 
19.25% to 33.5% (Fig. 12a; chi−square test, p<0.05). Figure 12b shows as STHdhQ111/111 cells 
has similar mitochondrial phenotype 6 days after transfection (p<0.05). 
We also measured JC−1 ratio in the STHdh cells transiently transfected with BNip3∆TM for three 
days. We observed that overexpression of BNip3∆TM in wild−type cells didn't modify JC−1 ratio 
whereas BNip3∆TM significantly increased JC−1 ratio in STHdhQ111/111 cells (Fig 12c; *p<0.05), 
without altering the mitochondrial mass content (data not shown). 
Although BNip3∆TM overexpression for 3 days improves mitochondrial membrane potential in  
STHdhQ111/111 cells, we observed also that its overexpression wasn’t able to increase ATP level 
in the same cells (Fig 12d). 
Finally, we analyzed oxygen consumption in STHdh cells. We observed that 3 days or 6 days of 
overexpression of BNip3∆TM in STHdhQ111/Q111 didn’t increase the oxygen consumption rate 
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(Fig. 12e-f). We repeated these measurements also after 11 days of expression of BNip3∆TM. To 
maintain high the level of the transgene we have repeated the transfection on the sixth day and 
then we have verified its expression by Western blot analysis. Our results demonstrated that 
BNip3∆TM causes a mild improvement in the oxygen consumption rate in STHdhQ111/Q111 cells 
( Fig 12g). 
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Fig. 1. Analysis of BNip3 expression and BNip3 integration into the mitochondrial membranes of human myoblasts. 
(a) Equal protein amounts from control and HD myoblasts were analyzed by WB and probed with anti-BNip3 antibody. The signal 
corresponding to monomeric BNip3 was higher in HD myoblasts (from left to right: 42 CAG, 42 CAG, 60 CAG and 48 CAG) than in 
control myoblasts. Actin was used as a loading control Protein band densitometry is reported in the corresponding graphs as 
means±SEM (* p<0.05). (b) Mitochondria-enriched fractions from control and HD myoblasts were analyzed by WB. Protein band 
densitometry is reported in the corresponding graphs as means±SEM. Dimeric BNip3 signal was clearly detectable in HD myoblasts 
(from left to right: 48 CAG, 60 CAG, 42 CAG and 42 CAG, * p<0.05). (c) Confocal microscopy on control  and HD (60 CAG) myoblasts. 
White arrows indicate regions of extended BNip3 and mitochondrial co-localization in HD myoblasts. The image is representative of four 
myoblast cultures from four HD patients.  
c 
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Fig. 2. Analysis of BNip3 level and BNip3 integration into the mitochondrial membrane in the brains of R6/2 and 
YAC128 mice. (a-b) Whole protein lysates of striatum and cortex from 10-week-old R6/2 and littermate control mice were analyzed by 
WB, using anti-BNip3 antibodies. There was a trend of decreasing monomeric BNip3 in R6/2 striatum (* p<0.05). No statistically 
significant difference in total BNip3 expression between R6/2 and wild-type mice was detected in cortical tissues. Data are 
representative of 6 R6/2 and 6 wild-type mice. (c-d) The panels show WB analysis of alkali-treated mitochondrial fractions from the 
striata and cortexes of 10-week-old R6/2 and control mice. To verify equal protein loading, the membranes were stripped and reprobed 
with anti-TOM20 antibody. Data are representative of six R6/2 and six wild-type mice analyzed (* p<0.05). (e-f) Immunoblotting and 
densitometric analysis of BNip3 expression in total lysates from striatum and cortex samples of five 6-month-old YAC128 mice and 
control littermates. Each lane represents one individual animal. Protein band densitometry results are reported in the corresponding 
graphs as means±SEM (two-tailed t-test, * p<0.05). (g-h) The panels show immunoblotting and densitometric analysis of BNip3 in alkali-
treated mitochondrial fractions from striata and cortexes of YAC128 and control mice. TOM20 was used as a loading control (two-tailed 
t-test, * p<0.05).   
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Fig. 3. Increased resistance of monomeric BNip3 to proteinase-K digestion in HD cells. Total cell extracts from four 
human myoblasts (a) and three R6/2 mouse brains (b) were digested in vitro for 8 min with increasing concentrations of PK. Lysis buffer 
contained 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 µg/ml pepstatin, 1 µg/ml leupeptin and 20 µM MG132. 
Densitometric analysis was performed on monomeric BNip3 signals. Multiple bands corresponding to monomeric forms were analyzed 
together. Data are reported as means±SEM, as percentages of the untreated sample. Monomeric BNip3 extracted from HD samples 
demonstrated increased resistance to PK digestion (* p<0.05 versus control sample). No difference in actin digestion patterns was 
detected between HD and control samples. 
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Fig. 4. Quantitative analysis of BNip3 mRNA. BNip3 mRNA was extracted from (a) human HD and control myoblasts, (b) 
R6/2 and control brains, (c) YAC128 and control brains. The level of each mRNA was normalized to that of cyclophilin A and actin. Data 
are presented as means±SEM (* p<0.01). 
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Fig. 5. Analysis of JC-1 fluorescence ratio in STHdhQ7/Q7 and STHdhQ111/Q111 cells. JC−1 is a mitochondrial dye that 
stains mitochondria in living cells in a membrane potential−dependent fashion. JC−1 monomer is in equilibrium with so−called 
J−aggregates, which are favored at higher mitochondrial membrane potential. The monomer JC−1 has green fluorescence (em = 527 
nm), while the J−aggregates have red fluorescence (em = 590 nm). JC−1 ratio is used to measure the ∆ψm. JC−1 ratio was measured 
in STHdh cells maintained in mild metabolic stress condition for three days. We observed that ∆ψm was decreased by ~ 70% in 
STHdhQ111/Q111 cells compared to STHdhQ7/Q7 (Data derive from six independent experiments. Fig. 5; **p< 0.01). 
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Fig. 6. Analysis mitochondrial content in HD cells. (a) Representative histogram obtained from STHdhQ7/Q7 and 
STHdhQ111/Q111 cells loaded with MitoTracker Green FM using flow cytometry. MitoTracker Green FM is a non-potentiometric 
fluorescent probe that stains mitochondria and its fluorescence is a measure of mitochondrial mass. STHdhQ111/Q111 cells have a 
reduced mitochondrial mass content compared to control cells. (b) Relative mtDNA content from myoblasts obtained from 8 control 
subjects and 6 HD patients. A difference was observed between control and HD myoblasts, but it is not statistically significant. 
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Fig. 7. Analysis of mitochondrial morphology in STHdhQ7/Q7 and STHdhQ111/Q111 cells. (a) Confocal image of  
DsRed protein-labeled mitochondria in STHdhQ7/Q7 and STHdhQ111/Q111 cells cultured for 3 days with mild metabolic strees 
medium. The images are representative of cells with fragmented and elongated mitochondria. Bar graph showing differences in 
mitochondrial morphologies in STHdhQ7/Q7 and STHdhQ111/Q111 cells after 3 (b) (chi-square test, p<0.01) or 6 days (c) (chi-square 
test, p<0.05) of treatment in galactose medium. 400 cells were counted for each condition. Data are presented as means±SEM. 
Computer-assisted quantitative analyses of mitochondrial morphology obtained using ImageJ 1.42 softare. FF is an indicator of 
mitochondrial length and branching, nc represents the number of mitochondria. STHdhQ111/Q111 cells displayed a slight decrease in 
FF (d) and nc (e) compared to STHdhQ7/Q7 cells. Data are presented as means±SEM ( * p<0.05).  
d 
 
 
 
 
 
 
 
 
e 
*
 
*
 
Clarissa Colciago         BNip3 as a target for HD 
 30
 
      
control HD
0
25
50
75
Class I
Class II
Class III
%
 
ce
lls
 
 
 
 
 
Fig. 8. Analysis of mitochondrial morphology in myoblasts obtained from human subjects. (a) Representative confocal 
image of  DsRed protein-labeled mitochondria in control and HD myoblasts. (b) Bar graph showing differences in mitochondrial 
morphologies. 300 cells were counted for each subject (3 control and 3 HD myoblasts). Data are presented as means±SEM (chi-square 
test, p<0.01). 
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Fig. 9. Analysis of ATP production in STHdh cells. (a) HPLC chromatograms of ATP in STHdhQ7/Q7 and 
STHdhQ111/Q111 cells. (b) Bar graph showing differences in ATP concentrations in STHdh cells after 3 days in mild metabolic stress 
medium. Data are presented as % means±SEM (*p<0.05). 
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Fig. 10. Analysis of oxygen consumption in STHdh cells. Bar graph showing oxygen consumption rate (OCR) in 
STHdhQ7/Q7 (8.996± 0.93 nmol/O2/106 cells) and STHdhQ111/Q111 cells (6.125± 0.79 nmol/O2/106 cells) after 3 days in mild metabolic 
stress medium. Data are presented as means±SEM (*p<0.05). 
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Fig. 11. BNip3∆TM overexpression improves mitochondrial function and morphology. (a) WB analysis of co-transfected 
myoblasts. (b) Analysis of ∆ψm in human HD (4 samples) and control (4 samples) myoblasts, after treatment with siRNA against BNip3 
together with a plasmid encoding BNip3∆TM. Data are presented as means±SEM (** p<0.01). Cultured cells were transfected with 
equal total amounts of plasmid DNA. (c) Bar graph showing differences in mitochondrial morphologies in myoblasts transfected with 
empty vector or BNip3 ∆TM. 300 cells were counted for each subject (3 control and 3 HD myoblasts). Data are presented as 
means±SEM (chi-square test, p<0.01). 
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Fig. 12. BNip3∆TM overexpression restores mitochondrial morphologyin STHdh cells cultured in mild metabolic 
stress medium. Bar graph showing differences in mitochondrial morphologies in transfected with empty vector or BNip3 ∆TM  for 3 (a) 
or 6 (b) days . 400 cells were counted per group. Data are presented as means±SEM (chi-square test, p<0.05). (c) Analysis of  ∆ψm in 
STHdhQ7/Q7 and STHdhQ111/Q111 cells 3 days after transfection  with empty vector or BNip3 ∆TM. Data are presented as 
means±SEM (* p<0.01).  (d) Bar graph showing differences in ATP concentrations in STHdh cells. Bar graph showing differences in 
oxygen consumption rate 3 (e) 6 (f ) and 11 (g) after transfection with BNip3∆TM  in STHdh cells.  
 
 
g 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clarissa Colciago         BNip3 as a target for HD 
 39
Conclusions and Future Prospects 
 
 
 
Many years have passed since the discovery of the HD mutation (HDCRG, 1993), however, no 
therapy to date has shown a neuroprotective effect or has been shown to slow down disease 
progression, most likely because the precise pathophysiological mechanisms of HD are poorly 
understood. Growing evidence suggests that mitochondrial function is compromised during early 
phases of HD pathogenesis (Browne, 2008), but how mhtt damages mitochondria is not yet 
understood. Evidence that accrued over the past few years increasingly favors the hypothesis that 
mitochondrial dysfunction has a key function in the death of the neuronal cells of HD patients 
(Browne, 2008; Bossy-Wetzel et al., 2008). Nevertheless, the nature of such mitochondrial damage 
has remained elusive so far. Our results suggest a role of BNip3 protein in the mitochondrial 
dysfunction induced by mhtt. Clinical and experimental studies have provided convincing evidence 
that mitochondrial dysfunction occurs in the CNS and skeletal muscle tissue of HD patients (Saft et 
al., 2005; Browne, 2008; Arenas et al., 1998; Lodi et al., 2000). Thus, cultures of human myoblasts 
obtained from HD patients are an excellent model to study the pathogenic effects of mhtt on the 
mitochondria. A former study showed a pathological decrease of ∆ψm in HD myoblasts (Ciammola 
et al., 2006). In this study, we provide evidence that BNip3 levels are increased in total lysates of 
HD myoblasts. More importantly, we demonstrate that more BNip3 colocalized with the 
mitochondria in human HD myoblasts when compared with age-matched control myoblasts. The 
increased total level of the BNip3 protein might depend both on transcriptional and on post-
transcriptional regulation. However, results indicating increased BNip3 translocation into the 
mitochondria and BNip3 integration into the OMM in HD cells suggest that post-transcriptional 
mechanisms are primarily involved. This hypothesis is further supported by the finding that the 
BNip3 protein in HD myoblasts is more resistant to PK digestion compared with that in control 
samples, probably because of the acquisition of an alternative conformation as a prelude to BNip3 
activation (Frazier et al., 2006). The results obtained from human HD myoblasts were confirmed in 
the brain tissue extracted from two different animal models of HD, R6/2 and YAC128 mice. In both 
animal models, we observed increased levels of dimeric BNip3 associated with striatal 
mitochondrial fractions. Importantly, YAC128 mice showed increased BNip3 levels in the striatum 
at 6 months of age when, in spite of overt motor symptoms, no striatal tissue loss had yet occurred. 
This suggests that alterations in BNip3 localization and activity may precede neural loss in HD.  
Unfortunately, a study on BNip3 in human HD brains cannot be conducted, as BNip3 expression 
and activation are strongly induced by hypoxic conditions that inevitably precede the collection of 
autopsy specimens. A large number of studies using cell culture models have shown that BNip3 
integration into the OMM leads to a potential loss of mitochondria (Vande Velde et al., 2000; Kim et 
al., 2002; Kubasiak et al., 2002; Kubli et al., 2007). In accordance with those results, a recent 
report described the spatial structure of BNip3 in a membrane-mimicking lipid environment, 
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showing that BNip3 homodimers can form an ion-conducting pathway in the membrane (Bocharov 
et al., 2007). In line with these studies, BNip3 translocation into the mitochondrial membrane and 
BNip3 dimerization may elicit the ∆ψm loss observed in animal and cell culture models of HD and in 
myoblasts extracted from HD patients. We observed increased levels of BNip3 homodimers in the 
mitochondrial fractions of all HD models investigated in our studies, including human HD 
myoblasts, R6/2 and YAC 128 mouse brains and transfected cell lines. These data suggest that 
BNip3 dimerization may be a crucial step in the BNip3 activation process induced by mhtt 
expression, even if a role for the monomeric form of BNip3 in mitochondrial damage cannot be 
ruled out. Moreover, an increased resistance of the BNip3 monomeric form to PK digestion was 
observed in lysates from R6/2 brains and HD myoblasts. Whether some of these monomers were 
derived from partial dissociation of the homodimers under denaturing and reducing conditions or 
rather represented the molecular precursors of dimers cannot be assessed. If our hypothesis 
positing that BNip3 has a role in ∆ψm loss in HD is correct, then the inhibition of BNip3 expression 
and/or BNip3 translocation and dimerization in HD cells should result in the increase in 
mitochondrial ∆ψm. BNip3∆TM is a dominant-negative mutant lacking the transmembrane domain 
required for BNip3 translocation and integration into the OMM (Kubasiak et al., 2002; Regula et al., 
2002). We observed that expression of BNip3∆TM and simultaneous downregulation of 
endogenous BNip3 by RNA interference in human HD muscle cells rescued the ∆ψm loss induced 
by mutant htt. Moreover the expression of BNip3∆TM was able to improve ∆ψm also in a cell line 
derived from the striatum of HD knock-in mice (STHdh)  that represents an useful tools for 
examining the molecular mechanisms of HD pathogenesis. 
The role of mitochondria in HD pathogenesis has long been investigated, but is poorly understood 
how mhtt can modulate mitochondrial network. Growing evidence indicates that the expression of 
mhtt results in changes to mitochondrial shape, with increased fragmentation and abnormal cristae 
arrangement. To investigate the effect of mhtt on mitochondrial dynamics in HD cells we examined 
changes in mitochondrial morphology. 
In this study we demonstrate that mhtt causes abnormal mitochondrial morphology in myoblasts 
from HD patients and HD striatal cell lines. We next verified if we could restore normal 
mitochondrial morphology by expressing BNip3∆TM in HD cells. In sum, these data demonstrate 
that mitochondrial morphology can be corrected in both the myoblasts from HD patients and the 
striatal cell model of HD by the efficient expression of a dominant-negative form of BNip3 that 
blocks BNip3 mitochondrial translocation.  
In conclusion, our results highlighted that BNip3∆TM expression for three days led to a significant 
change in mitochondrial morphologya slight (but significant) increased in JC−1 ratio and no 
changes in mitochondrial mass content , ATP synthesis and oxygen consumption in 
STHdhQ111/111 cells. No significant changes were observed in wild type STHdhQ7/7 cells. We 
believe, that the beneficial effects we observed in STHdhQ111/111 depend on the ability of 
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BNip3∆TM to block the OMM permeabilization induced by BNip3. The low JC1 red/green that we 
detected in STHdhQ111/111 cells compared to STHdhQ7/7 cells likely depend on both 
mitochondrial depolarization and low mitochondrial content. But, the increase of the JC−1 ratio 
induced by BNip3∆TM (Fig. 12c) likely reflects a real ∆ψm increase, since the mitochondrial mass 
content did not change both in STHdhQ7/7 cells and STHdhQ111/111 cells after three days of 
BNip3∆TM expression. 
These data support a role for BNip3 in htt-induced mitochondrial damage and point to a new 
potential gene therapy approach for HD. In the future, further investigations will be necessary to 
address BNip3 as potential target for neuroprotective therapy redirecting mhhtt cells towards 
survival. It is important to note that BNip3 knock-out mice are viable and lack a pathological 
phenotype (Diwan et al., 2007); thus, the inhibition of BNip3 function by RNA interference or by 
overexpression of the dominant-negative mutant BNip3∆TM may have neuroprotective effects 
without causing adverse side effects.  
One question that remains unanswered is how mhtt induces BNip3 activation. Previous reports 
have shown that BNip3 association with mitochondria is strongly stabilized by acidosis or by an 
increased cytosolic calcium concentration. Both conditions may occur in HD cells, causing BNip3 
stabilization and integration into the OMM, but one more intriguing possibility should also be 
considered: in light of the fact that htt can localize to the mitochondria by loosely associating with 
the OMM, we may hypothesize that htt binds directly or indirectly to BNip3. Future studies will aim 
at elucidating these and other potential mechanisms underlying the effects of mutant htt on BNip3. 
Moreoverer the effect of BNip3∆TM on mitochondrial morphology in HD cells has to be verified by 
ultrastructural analysis (electron microscopy), but will be necessary a viral vector encoding 
BNip3∆TM to infect HD cells. A viral infection will help to demonstrate whether a stable expression 
of BNip3∆TM can correct mitochondrial function such as ATP production and oxygen consumption. 
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